Structure of: (a) CYD -TDV (Dengvaxia); (b) TAK -003; (c) TV003 / TV005... | Download Scientific Diagram
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
TAK-003 vaccine: Trial shows Continued Protection against Dengue Fever - YouTube
gemirdaypresentation
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) | PLOS Neglected Tropical Diseases
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
PharmaShots. - • The submission is based on a P-III TIDES trial assessing TAK-003 (0.5ml, SC) vs PBO in 20,000+ healthy children & adolescents aged 4-16yrs. to prevent dengue fever of any
Cross-reactivity of T cell responses following TAK-003... | Download Scientific Diagram
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
Takeda: Dengue Vaccine Candidate Works Without Big Safety Risks
Takeda's dengue shot keeps 84% of kids out of hospital regardless of prior infection, giving it a leg up over Sanofi's Dengvaxia | Fierce Biotech
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | NEJM
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration - Headlines of Today
Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
FDA grants priority review to Takeda's dengue vaccine – PharmaLive
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
TAK-003 - News, Articles etc. - European Pharmaceutical Review
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior Infection
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration
Takeda's tetravalent dengue vaccine (TAK-003) receives first global approval for use in Indonesia without need for pre-vaccination testing | Asia Research News
VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | 2 Minute Medicine
Takeda's dengue vaccine prevents hospitalisations in TIDES trial
